Sergio S Dertkigil Selected Research

Complement C1s (C1 Esterase)

1/2021	Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.
1/2021	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sergio S Dertkigil Research Topics

Disease

3	COVID-19 01/2022 - 01/2021
1	Cough 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Hereditary Angioedemas 01/2021
1	Inflammation (Inflammations) 01/2021
1	Heart Failure 01/2019

Drug/Important Bio-Agent (IBA)

2	Kallikreins (Kallikrein)IBA 01/2021 - 01/2021
2	BradykininIBA 01/2021 - 01/2021
2	Complement C1s (C1 Esterase)IBA 01/2021 - 01/2021
2	icatibantIBA 01/2021 - 01/2021
1	Angiotensin IIIBA 01/2022
1	AngiotensinsIBA 01/2022
1	angiotensin I (1-7)IBA 01/2022
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021
1	LipopolysaccharidesIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021
1	KininsIBA 01/2021

Therapy/Procedure

1	Therapeutics 01/2019
1	Exercise Therapy (Therapy, Exercise) 01/2019